279 related articles for article (PubMed ID: 28062546)
21. DXA Measured Visceral Adipose Tissue, Total Fat, Anthropometric Indices and its Association With Cardiometabolic Risk Factors in Mother-Daughter Pairs From India.
Shetty S; Kapoor N; Thomas N; Paul TV
J Clin Densitom; 2021; 24(1):146-155. PubMed ID: 32651111
[TBL] [Abstract][Full Text] [Related]
22. Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.
Collins L; Basaria S
Asian J Androl; 2012 Mar; 14(2):222-5. PubMed ID: 22343494
[TBL] [Abstract][Full Text] [Related]
23. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
Owen PJ; Daly RM; Livingston PM; Fraser SF
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.
Corona G; Gacci M; Baldi E; Mancina R; Forti G; Maggi M
J Sex Med; 2012 Mar; 9(3):887-902. PubMed ID: 22248394
[TBL] [Abstract][Full Text] [Related]
25. Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV.
Fourman LT; Kileel EM; Hubbard J; Holmes T; Anderson EJ; Looby SE; Fitch KV; Feldpausch MN; Torriani M; Lo J; Stanley TL; Grinspoon SK
Nutr Diabetes; 2019 Feb; 9(1):6. PubMed ID: 30804324
[TBL] [Abstract][Full Text] [Related]
26. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
[TBL] [Abstract][Full Text] [Related]
27. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
29. Visceral fat reference values derived from healthy European men and women aged 20-30 years using GE Healthcare dual-energy x-ray absorptiometry.
Miazgowski T; Kucharski R; Sołtysiak M; Taszarek A; Miazgowski B; Widecka K
PLoS One; 2017; 12(7):e0180614. PubMed ID: 28683146
[TBL] [Abstract][Full Text] [Related]
30. Exercise Improves V˙O2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients.
Wall BA; GALVãO DA; Fatehee N; Taaffe DR; Spry N; Joseph D; Hebert JJ; Newton RU
Med Sci Sports Exerc; 2017 Aug; 49(8):1503-1510. PubMed ID: 28319589
[TBL] [Abstract][Full Text] [Related]
31. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
32. Increased visceral adipose tissue and altered adiposity distribution in premenopausal lupus patients: correlation with cardiovascular risk factors.
Seguro LPC; Paupitz JA; Caparbo VF; Bonfa E; Pereira RMR
Lupus; 2018 May; 27(6):1001-1006. PubMed ID: 29451068
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
34. Correlation of visceral adipose tissue measured by Lunar Prodigy dual X-ray absorptiometry with MRI and CT in older men.
Cheung AS; de Rooy C; Hoermann R; Gianatti EJ; Hamilton EJ; Roff G; Zajac JD; Grossmann M
Int J Obes (Lond); 2016 Aug; 40(8):1325-8. PubMed ID: 27003112
[TBL] [Abstract][Full Text] [Related]
35. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
38. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
39. Ectopic fat and cardiometabolic and vascular risk.
Lim S; Meigs JB
Int J Cardiol; 2013 Nov; 169(3):166-76. PubMed ID: 24063931
[TBL] [Abstract][Full Text] [Related]
40. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass?
Park YW; Heymsfield SB; Gallagher D
Int J Obes Relat Metab Disord; 2002 Jul; 26(7):978-83. PubMed ID: 12080453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
